we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have
![Atara Biotherapeutics logo](/files/LOGO/1604464-ATRA.png)
Company profile
Ticker
ATRA
Exchange
Website
CEO
Pascal Touchon
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Atara Biotherapeutics Australia • Atara Biotherapeutics Ireland Limited • Atara Biotherapeutics Switzerland GmbH ...
ATRA stock data
Latest filings (excl ownership)
8-K
Material Modifications to Rights of Security Holders
20 Jun 24
8-K
Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
17 Jun 24
S-8
Registration of securities for employees
11 Jun 24
S-8
Registration of securities for employees
11 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
10 Jun 24
DEFR14A
Revised proxy
10 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
9 May 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
Transcripts
ATRA
Earnings call transcript
2023 Q3
1 Nov 23
ATRA
Earnings call transcript
2022 Q3
9 Nov 22
ATRA
Earnings call transcript
2022 Q2
8 Aug 22
ATRA
Earnings call transcript
2022 Q1
6 May 22
ATRA
Earnings call transcript
2021 Q4
1 Mar 22
ATRA
Earnings call transcript
2021 Q3
4 Nov 21
ATRA
Earnings call transcript
2021 Q2
10 Aug 21
ATRA
Earnings call transcript
2021 Q1
5 May 21
ATRA
Earnings call transcript
2020 Q4
2 Mar 21
ATRA
Earnings call transcript
2020 Q3
10 Nov 20
Latest ownership filings
SC 13D
Adiumentum Capital Fund I LP
22 May 24
4
Pascal Touchon
20 May 24
4
AnhCo Nguyen
20 May 24
4
Amar Murugan
20 May 24
4
Eric J Hyllengren
20 May 24
4
Jill Henrich
20 May 24
144
Notice of proposed sale of securities
16 May 24
144
Notice of proposed sale of securities
16 May 24
144
Notice of proposed sale of securities
16 May 24
144
Notice of proposed sale of securities
16 May 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 35.23 mm | 35.23 mm | 35.23 mm | 35.23 mm | 35.23 mm | 35.23 mm |
Cash burn (monthly) | (no burn) | 1.14 mm | 10.58 mm | 19.45 mm | 9.87 mm | 15.35 mm |
Cash used (since last report) | n/a | 3.18 mm | 29.52 mm | 54.28 mm | 27.55 mm | 42.83 mm |
Cash remaining | n/a | 32.06 mm | 5.72 mm | -19.05 mm | 7.68 mm | -7.60 mm |
Runway (months of cash) | n/a | 28.2 | 0.5 | -1.0 | 0.8 | -0.5 |
Institutional ownership, Q1 2024
7.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 23 |
Opened positions | 18 |
Closed positions | 4 |
Increased positions | 2 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 1.92 bn |
Total shares | 9.29 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Citadel Advisors | 6.51 mm | $4.96 mm |
Staley Capital Advisers | 1.00 mm | $694.00 mm |
TD Asset Management | 436.80 k | $303.14 mm |
BNP Paribas Arbitrage | 383.08 k | $265.86 mm |
BK Bank Of New York Mellon | 352.51 k | $244.64 mm |
Savant Capital | 131.81 k | $91.48 mm |
Hennion & Walsh Asset Management | 119.05 k | $82.62 mm |
Private Advisor | 95.66 k | $66.39 mm |
New York State Common Retirement Fund | 39.68 k | $28.00 k |
State Board Of Administration Of Florida Retirement System | 31.15 k | $90.32 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 May 24 | Pascal Touchon | Common Stock | Sell | Dispose S | No | No | 0.617 | 81,506 | 50.29 k | 1,829,146 |
16 May 24 | AnhCo Nguyen | Common Stock | Sell | Dispose S | No | No | 0.617 | 42,899 | 26.47 k | 898,498 |
16 May 24 | Eric J Hyllengren | Common Stock | Sell | Dispose S | No | No | 0.617 | 28,648 | 17.68 k | 645,671 |
16 May 24 | Jill Henrich | Common Stock | Sell | Dispose S | No | No | 0.617 | 25,750 | 15.89 k | 529,251 |
16 May 24 | Amar Murugan | Common Stock | Sell | Dispose S | No | No | 0.617 | 32,401 | 19.99 k | 695,120 |
News
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
17 Jun 24
12 Health Care Stocks Moving In Monday's Intraday Session
17 Jun 24
12 Health Care Stocks Moving In Friday's After-Market Session
31 May 24
Atara Biotherapeutics To Present Preclinical Data On ATA3219, An Allogeneic CD19-Targeted CAR T Therapy For The Treatment Of B-Cell Driven Autoimmune Diseases, At The ISCT 2024 Annual Meeting
29 May 24
HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeutics
22 May 24
Press releases
Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
17 Jun 24
Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
12 Jun 24
Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now
11 Jun 24
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
7 Jun 24
Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
5 Jun 24